The agreement ensures sales and marketing coverage for Stereotaxis in an electrophysiology (EP) market performing approximately 47,000 procedures each year and expected to grow at an annual rate of 10% through 2018.

Under the agreement, Hokushin Medical will market, sell and distribute the Niobe system and disposable devices to Japanese customers, as well as provide customer training and clinical support. Medix Japan will lead the completion of the post marketing surveillance project as required by Japan’s Pharmaceuticals and Medical Devices Agency.

Furthermore, Medix Japan will be charged with securing market authorization of Stereotaxis’ Vdrive™ Robotic Navigation System and Odyssey® Information Management Solution in the coming months, in order to offer the advantages of the full Epoch™ Solution to the Japanese market.

Stereotaxis CEO William C Mills noted the company is very pleased to have the assistance of Medix Japan and Hokushin Medical in bringing its expertise with automated, remote navigation solutions to the Japanese EP community.

"With an aging population and increasing rate of arrhythmias and other cardiac conditions, we can offer EP physicians in Japan greater possibilities in the treatment of their complex cases and make a difference in patient quality of life. We are confident that these two companies, both experts in product promotion with deep understanding of the Japanese medical device industry and strong entrepreneurial spirit, will enthusiastically support our vision in a vital new market," Mills added.